{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:33:42Z","timestamp":1787582022296,"version":"build-2736575974"},"reference-count":79,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mastocytosis is a heterogeneous group of disorders, distinguished by the monoclonal proliferation of mast cells (MCs) in one or more organs. While cutaneous mastocytosis (CM) is restricted to the skin, systemic mastocytosis (SM) presents with high MC infiltration of various organs. Indolent systemic mastocytosis (ISM) is the most common form in individuals with adult-onset of the disease. Bone health impairment is present in the vast majority of patients, ranging from osteoporosis to osteosclerosis, often presenting with fragility fractures. In this review, we comprehensively examine the impact of ISM on bone health, with particular emphasis on the molecular and cellular mechanisms underlying skeletal involvement, the clinical heterogeneity of bone manifestations, and the limitations of current diagnostic tools, while also evaluating emerging therapeutic strategies that target both MC activity and bone remodeling pathways.<\/jats:p>","DOI":"10.3390\/ijms26125649","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T11:47:07Z","timestamp":1749728827000},"page":"5649","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Indolent Mastocytosis and Bone Health: Molecular Mechanisms and Emerging Treatment Options"],"prefix":"10.3390","volume":"26","author":[{"given":"Lucia","family":"Jankovski","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Rakusa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrijana","family":"Koceva","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology, University Medical Center Maribor, 2000 Maribor, Slovenia"},{"name":"Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-5254","authenticated-orcid":false,"given":"Andrej","family":"Jane\u017e","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-6689","authenticated-orcid":false,"given":"Peter","family":"Kopa\u010d","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Allergology Department, University Hospital of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-8803","authenticated-orcid":false,"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Baran, J., Sobiepanek, A., Mazurkiewicz-Pisarek, A., Rogalska, M., Gryciuk, A., Kuryk, L., Abraham, S.N., and Staniszewska, M. (2023). Mast Cells as a Target\u2014A Comprehensive Review of Recent Therapeutic Approaches. Cells, 12.","DOI":"10.3390\/cells12081187"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dileepan, K.N., Raveendran, V.V., Sharma, R., Abraham, H., Barua, R., Singh, V., Sharma, R., and Sharma, M. (2023). Mast cell-mediated immune regulation in health and disease. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1213320"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ribatti, D., and d\u2019Amati, A. (2023). Hematopoiesis and Mast Cell Development. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310679"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaci.2018.10.054","article-title":"Mast cells as protectors of health","volume":"144","author":"Dudeck","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11882-024-01183-5","article-title":"Mast Cells and Mas-related G Protein-coupled Receptor X2: Itching for Novel Pathophysiological Insights to Clinical Relevance","volume":"25","author":"Castells","year":"2025","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"M\u00e9ndez-Enr\u00edquez, E., and Hallgren, J. (2019). Mast Cells and Their Progenitors in Allergic Asthma. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00821"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaci.2024.10.025","article-title":"Targeting of the IL-5 pathway in severe asthma reduces mast cell progenitors","volume":"155","author":"Salomonsson","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/eji.202048668","article-title":"Mast cells crosstalk with B cells in the gut and sustain IgA response in the inflamed intestine","volume":"51","author":"Valeri","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hellman, L., Akula, S., Fu, Z., and Wernersson, S. (2022). Mast Cell and Basophil Granule Proteases\u2014In Vivo Targets and Function. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.918305"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-019-08729-w","article-title":"A Review of the Contribution of Mast Cells in Wound Healing: Involved Molecular and Cellular Mechanisms","volume":"58","author":"Komi","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ragipoglu, D., B\u00fclow, J., Hauff, K., Voss, M., Haffner-Luntzer, M., Dudeck, A., Ignatius, A., and Fischer, V. (2022). Mast Cells Drive Systemic Inflammation and Compromised Bone Repair After Trauma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.883707"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: State of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Li, J.Y., Ryder, C.B., Zhang, H., Cockey, S.G., Hyjek, E., Moscinski, L.C., Sagatys, E., and Song, J. (2023). Review and Updates on Systemic Mastocytosis and Related Entities. Cancers, 15.","DOI":"10.3390\/cancers15235626"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108892","DOI":"10.1016\/j.pharmthera.2025.108892","article-title":"Current and future therapeutics targeting mast cells in disease","volume":"273","author":"Worrall","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_18","first-page":"556141","article-title":"The 2023 Updated Classification and Diagnostic Criteria of Mastocytosis","volume":"24","author":"Hamed","year":"2023","journal-title":"Cancer Ther. Oncol. Int. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: From molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, Prognosis, and Risk Factors in Mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/187152806775269303","article-title":"Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis","volume":"5","author":"Escribano","year":"2006","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hermine, O., Lortholary, O., Leventhal, P.S., Catteau, A., Soppelsa, F., Baude, C., Cohen-Akenine, A., Palm\u00e9rini, F., Hanssens, K., and Yang, Y. (2008). Case-Control Cohort Study of Patients\u2019 Perceptions of Disability in Mastocytosis. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002266"},{"key":"ref_24","first-page":"126","article-title":"Mastocytosis presenting as a skeletal disorder","volume":"16","author":"Delsignore","year":"1996","journal-title":"Iowa Orthop. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","article-title":"Prevalence of indolent systemic mastocytosis in a Dutch region","volume":"131","author":"Arends","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zanotti, R., Bonifacio, M., Isolan, C., Tanasi, I., Crosera, L., Olivieri, F., Orsolini, G., Schena, D., and Bonadonna, P. (2021). A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years\u2019 Experience of the GISM Network. Cancers, 13.","DOI":"10.3390\/cancers13246380"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/all.16084","article-title":"High burden of clonal mast cell disorders and hereditary \u03b1-tryptasemia in patients who need Hymenoptera venom immunotherapy","volume":"79","author":"Sturm","year":"2024","journal-title":"Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11914-025-00901-w","article-title":"Management of Bone Health in Adult Mastocytosis","volume":"23","author":"Nezzar","year":"2025","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Szudy-Szczyrek, A., Mlak, R., Pigo\u0144-Zaj\u0105c, D., Krupski, W., Mazurek, M., Tomczak, A., Chromik, K., G\u00f3rska, A., Ko\u017alik, P., and Juda, A. (2025). Role of sclerostin in mastocytosis bone disease. Sci. Rep., 15.","DOI":"10.1038\/s41598-024-83851-0"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ragipoglu, D., Dudeck, A., Haffner-Luntzer, M., Voss, M., Kroner, J., Ignatius, A., and Fischer, V. (2020). The Role of Mast Cells in Bone Metabolism and Bone Disorders. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00163"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jaip.2023.02.007","article-title":"Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis","volume":"11","author":"Rama","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00223-021-00887-4","article-title":"Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis","volume":"109","author":"Gehlen","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","article-title":"Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis","volume":"24","author":"Seitz","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.morpho.2020.01.004","article-title":"Bone lesions in systemic mastocytosis: Bone histomorphometry and histopathological mechanisms","volume":"104","author":"Bouvard","year":"2020","journal-title":"Morphologie"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.55563\/clinexprheumatol\/y4ksv9","article-title":"Bone mineral density in patients with systemic mastocytosis: Correlations with clinical and histopathological features","volume":"39","author":"Meyer","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-019-03119-3","article-title":"An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis","volume":"146","author":"Riffel","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","year":"2012","journal-title":"Allergy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","article-title":"Bone Involvement and Osteoporosis in Mastocytosis","volume":"34","author":"Rossini","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1056\/ENEJMicm010831","article-title":"Systemic Mastocytosis","volume":"349","author":"Deb","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","article-title":"Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis","volume":"134","author":"Arends","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrrheum.2012.167","article-title":"New developments in osteoimmunology","volume":"8","author":"Takayanagi","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev. Cell"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Guillaume, N., Desoutter, J., Chandesris, O., Merlusca, L., Henry, I., Georgin-Lavialle, S., Barete, S., Hirsch, I., Bouredji, D., and Royer, B. (2013). Bone Complications of Mastocytosis: A Link between Clinical and Biological Characteristics. Am. J. Med., 126.","DOI":"10.1016\/j.amjmed.2012.07.018"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Letizia Mauro, G., Accomando, J., Tomasello, S., Duca, A., Mangano, M.S., De Sire, A., Vecchio, M., and Scaturro, D. (2024). Osteoporosis in Systemic Mastocytosis: A Scoping Review. Medicina, 60.","DOI":"10.3390\/medicina60111752"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/\u03b2-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","article-title":"Involvement of WNT\/\u03b2-catenin Signaling in the Treatment of Osteoporosis","volume":"93","author":"Rossini","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41467-021-22754-4","article-title":"Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","article-title":"Histamine Promotes Osteoclastogenesis through the Differential Expression of Histamine Receptors on Osteoclasts and Osteoblasts","volume":"174","author":"Baroukh","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semarthrit.2006.03.004","article-title":"The Role of Mast Cells in Osteoporosis","volume":"36","author":"Chiappetta","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.11604\/pamj.2019.32.169.16640","article-title":"Systemic mastocytosis: A rare cause of osteoporosis","volume":"32","author":"Garla","year":"2019","journal-title":"Pan Afr. Med. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5785378","DOI":"10.1155\/2020\/5785378","article-title":"Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients","volume":"2020","author":"Carosi","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00223-016-0198-3","article-title":"Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis","volume":"100","author":"Artuso","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"ref_58","first-page":"2276","article-title":"Systemic Mastocytosis: Predominantly Involving the Bone, A Case Report","volume":"7","author":"Mallya","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1016\/j.jaip.2020.06.054","article-title":"Fracture Risk Reduction by Bisphosphonates in Mastocytosis?","volume":"8","author":"Onnes","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1210\/jc.2006-1178","article-title":"Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry","volume":"91","author":"Lewiecki","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00223-023-01107-x","article-title":"Assessment of Bone Microarchitecture in Patients with Systemic Mastocytosis and its Association with Clinical and Biochemical Parameters of the Disease","volume":"113","author":"Franco","year":"2023","journal-title":"Calcif. Tissue Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.clinimag.2014.12.006","article-title":"MR-based trabecular bone microstructure is not altered in subjects with indolent systemic mastocytosis","volume":"39","author":"Baum","year":"2015","journal-title":"Clin. Imaging"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00223-020-00749-5","article-title":"Usefulness of Dual X-ray Absorptiometry-Derived Bone Geometry and Structural Indexes in Mastocytosis","volume":"107","author":"Ulivieri","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Brandi, M.L., and Khan, A. (2024). Mastocytosis and the Bone: Observational Study. Bone Metabolism, Parathyroid Glands, and Calciotropic Hormones, Springer Nature.","DOI":"10.1007\/978-3-030-19632-5"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/ard.2004.029116","article-title":"Systemic mastocytosis: A rare cause of osteoporosis and its response to bisphosphonate treatment","volume":"64","author":"Lim","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9492883","DOI":"10.1155\/2021\/9492883","article-title":"Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis","volume":"2021","author":"Ferreira","year":"2021","journal-title":"J. Osteoporos."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Rossini, M., Zanotti, R., Viapiana, O., Tripi, G., Idolazzi, L., Biondan, M., Orsolini, G., Bonadonna, P., Adami, S., and Gatti, D. (2014). Zoledronic Acid in Osteoporosis Secondary to Mastocytosis. Am. J. Med., 127.","DOI":"10.1016\/j.amjmed.2014.06.015"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/jbmr.49","article-title":"The role of mast cells in parathyroid bone disease","volume":"25","author":"Turner","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","article-title":"Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis","volume":"26","author":"Laroche","year":"2006","journal-title":"Clin. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V120.21.799.799","article-title":"KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial","volume":"120","author":"Gotlib","year":"2012","journal-title":"Blood"},{"key":"ref_73","first-page":"22","article-title":"Skin and bones: Systemic mastocytosis and bone","volume":"2023","author":"Wang","year":"2023","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2023-eular.3302","article-title":"POS0496 Management of Osteoporosis in Patients with Systemic Mastocytosis: A Monocentric Expert Centre Experience","volume":"82","author":"Nezzar","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus Placebo in Indolent Systemic Mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1182\/blood-2022-156326","article-title":"Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)","volume":"140","author":"Akin","year":"2022","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"AB221","DOI":"10.1016\/j.jaci.2021.12.721","article-title":"A Phase 2\/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome","volume":"149","author":"Castells","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: A proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5649\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:51:02Z","timestamp":1760032262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":79,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26125649"],"URL":"https:\/\/doi.org\/10.3390\/ijms26125649","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}